AP
AZN icon

Anchyra Partners’s AstraZeneca AZN Stock Holding History

Anchyra Partners’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$543K Sell
2,861
-140
-5% -$26.3K 0.13% 141
2026
Q1 		$592K Buy
3,001
+168
+6% +$32.4K 0.18% 118
2025
Q4 		$521K Buy
+2,833
New +$497K 0.16% 126

Other funds holding AZN

EPGL
Evelyn Partners Group Ltd London $46.9B AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
CDDEC
Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Anchyra Partners's AZN Position: Q2 2026 in Review

Anchyra Partners reduced its AstraZeneca (AZN) stake by 4.7% in Q2 2026, selling an estimated $26.3K and leaving 2,861 shares worth $543K. The position accounts for 0.13% of the portfolio, ranked #141.

Anchyra Partners first reported a position in AZN in Q4 2025 and has held it in 3 quarters since. The position peaked at $592K in Q1 2026. 906 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Anchyra Partners held 2,861 shares of AstraZeneca worth $543K as of Q2 2026.
  • Anchyra Partners sold 140 AstraZeneca shares in Q2 2026, an estimated $26.3K.
  • AstraZeneca made up 0.13% of Anchyra Partners's portfolio in Q2 2026, its #141 holding.
  • Anchyra Partners first reported a position in AstraZeneca in Q4 2025 and has held it in 3 quarters since.
  • Anchyra Partners's AstraZeneca position peaked at $592K in Q1 2026.
  • 906 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Anchyra Partners's 13F filing for Q2 2026, filed 23 Jul 2026.